Impacto Públicocivic observatory
Portuguêspt-PTEnglishcurrent languageEspañoles-ES

PUBLIC CONTRACT · 2025

Sirolimus, Brigatinib, Nintedanib, Durvalumab e Lorlatinib

Contract value
€266,325.59
Signed on
16 October 2025
Procedure
Ao abrigo de acordo-quadro (art.º 259.º)

This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.

Record 11963479

PUBLISHED SUBJECT

41/4931/2025 - Sirolimus, Brigatinib, Nintedanib, Durvalumab e Lorlatinib

Parties involved

Place of performance
Portugal, Faro, Faro
NUTS region
PT150 - Algarve

WHO BID

Awardee and competitors

Companies that IMPIC lists as the awardee and as competitors in this procedure.

Awardee
LAB. PFIZER, LDA. · Tax ID 500162166
Awardee
TAKEDA-FARMACEUTICOS PORTUGAL, LDA · Tax ID 502801204
Awardee
ASTRAZENECA-PRODUTOS FARMACÊUTICOS,LDA. · Tax ID 502942240
Awardee
BOERINGER INGLHEIM PORTUGAL · Tax ID 500293023

Values and timeline

Contract price
€266,325.59
Procedure base price
€266,325.59
Total effective price
Not reported on Portal BASE
Publication date
20 November 2025
Award date
16 October 2025
Signing date
16 October 2025
Performance period
92 days

The contract price is the value agreed in the contract, not the amount paid.

Procedure and framework

Contract type
Aquisição de bens móveis
Procedure type
Ao abrigo de acordo-quadro (art.º 259.º)
Award criterion
Monofator
CPV code
33690000-3 - Medicamentos vários
Legal basis
Artigo 259.º do Código dos Contratos Públicos
Regime
Código dos Contratos Públicos ( DL 111-B/2017 )
Framework agreement
491/2023 - Concurso público internacional para formação do acordo quadro de medicamentos do foro oncológico e imunomoduladores
Centralised procedure
No
Environmental criterion
No
Notice
Not stated
Procedure identifier
8062212

Compare with other contracts

Search the same body, supplier, place or type of service to understand the context of the published index.

← Back to contracts